Wall Street Zen downgraded shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) from a hold rating to a sell rating in a research note released on Saturday,Wall Street Zen reports.
Other equities analysts have also issued reports about the company. JPMorgan Chase & Co. started coverage on Nektar Therapeutics in a report on Friday, August 21st. They issued a “neutral” rating and a $65.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nektar Therapeutics in a report on Friday, August 28th. UBS Group started coverage on Nektar Therapeutics in a research report on Monday, October 12th. They set a “neutral” rating and a $53.00 target price for the company. TD Cowen upgraded Nektar Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Finally, Leerink Partners began coverage on Nektar Therapeutics in a research note on Monday, October 12th. They set an “outperform” rating and a $130.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $130.67.
View Our Latest Stock Analysis on NKTR
Nektar Therapeutics Stock Up 0.1%
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The biopharmaceutical company reported ($1.63) EPS for the quarter, beating the consensus estimate of ($2.07) by $0.44. Nektar Therapeutics had a negative net margin of 339.67% and a negative return on equity of 33.89%. The firm had revenue of $9.39 million during the quarter, compared to analyst estimates of $10.27 million. As a group, research analysts predict that Nektar Therapeutics will post -8.08 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Nektar Therapeutics news, CEO Howard Robin sold 418 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $71.98, for a total transaction of $30,087.64. Following the completion of the transaction, the chief executive officer directly owned 54,627 shares of the company’s stock, valued at approximately $3,932,051.46. This represents a 0.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 2.50% of the company’s stock.
Institutional Trading of Nektar Therapeutics
Several hedge funds have recently made changes to their positions in NKTR. Orbimed Advisors LLC purchased a new stake in shares of Nektar Therapeutics in the 1st quarter worth about $19,786,000. Two Seas Capital LP boosted its stake in shares of Nektar Therapeutics by 8.2% during the 3rd quarter. Two Seas Capital LP now owns 3,345,978 shares of the biopharmaceutical company’s stock valued at $202,582,000 after purchasing an additional 253,744 shares in the last quarter. Braidwell LP increased its position in shares of Nektar Therapeutics by 112.7% during the second quarter. Braidwell LP now owns 473,617 shares of the biopharmaceutical company’s stock valued at $33,063,000 after buying an additional 250,916 shares during the period. Bank of New York Mellon Corp purchased a new position in shares of Nektar Therapeutics during the second quarter valued at about $6,706,000. Finally, ACT Capital Partners L.P. purchased a new position in shares of Nektar Therapeutics during the third quarter valued at about $5,473,000. 75.88% of the stock is currently owned by institutional investors.
More Nektar Therapeutics News
Investors following NKTR have been watching these news items:
- Positive Sentiment: Nektar’s loss of $1.63 per share was narrower than analysts’ estimates. The company also said it had initiated all three Phase 3 ZENITH trials for rezpegaldesleukin in atopic dermatitis, with an alopecia areata trial planned for December. Zacks Q3 results and outlook
- Positive Sentiment: The company reported $952.9 million in cash and marketable securities at quarter-end, providing resources to advance its clinical programs. Nektar Q3 financial results
- Negative Sentiment: Nektar cut its 2026 revenue outlook, a key reason shares were reported down 4.5%. Quarterly revenue of $9.4 million missed the roughly $10.3 million consensus and declined from $11.8 million a year earlier. Zacks Q3 results and outlook
Nektar Therapeutics Company Profile
Nektar Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco, California. It discovers and develops medicines, with a current focus on treatments for autoimmune and inflammatory diseases. Its lead investigational program, rezpegaldesleukin (REZPEG), is designed to stimulate regulatory T cells, which help regulate immune responses. Nektar is studying the candidate in clinical trials for immune-mediated conditions; it is not an approved medicine. Founded in 1990 as Inhale Therapeutic Systems, the company later adopted the Nektar name as it expanded its drug-development work.
Featured Articles
- Five stocks we like better than Nektar Therapeutics
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
- Why Equinix and Digital Realty Benefit From Data Center Zoning Battles
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
